Literature DB >> 12960187

Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG.

Andreas K Buck1, Gisela Halter, Holger Schirrmeister, Jörg Kotzerke, Imke Wurziger, Gerhard Glatting, Torsten Mattfeldt, Bernd Neumaier, Sven N Reske, Martin Hetzel.   

Abstract

UNLABELLED: Recently, the thymidine analog 3'-deoxy-3'-(18)F-fluorothymidine (FLT) was suggested for imaging tumoral proliferation. In this prospective study, we examined whether (18)F-FLT better determines proliferative activity in newly diagnosed lung nodules than does (18)F-FDG.
METHODS: Twenty-six patients with pulmonary nodules on chest CT were examined with PET and the tracers (18)F-FDG and (18)F-FLT. Tumoral uptake was determined by calculation of standardized uptake value (SUV). Within 2 wk, patients underwent resective surgery or had core biopsy. Proliferative activity was estimated by counting nuclei stained with the Ki-67-specific monoclonal antibody MIB-1 per total number of nuclei in representative tissue specimens. The correlation between the percentage of proliferating cells and the SUVs for (18)F-FLT and (18)F-FDG was determined using linear regression analysis.
RESULTS: Eighteen patients had malignant tumors (13 with non-small cell lung cancer [NSCLC], 1 with small cell lung cancer, and 4 with pulmonary metastases from extrapulmonary tumors); 8 had benign lesions. In all visible lesions, mean (18)F-FDG uptake was 4.1 (median, 4.4; SD, 3.0; range, 1.0-10.6), and mean (18)F-FLT uptake was 1.8 (median, 1.2; SD, 2.0; range, 0.8-6.4). Statistical analysis revealed a significantly higher uptake of (18)F-FDG than of (18)F-FLT (Mann-Whitney U test, P < 0.05). (18)F-FLT SUV correlated better with proliferation index (P < 0.0001; r = 0.92) than did (18)F-FDG SUV (P < 0.001; r = 0.59). With the exception of 1 carcinoma in situ, all malignant tumors showed increased (18)F-FDG PET uptake. (18)F-FLT PET was false-negative in the carcinoma in situ, in another NSCLC with a low proliferation index, and in a patient with lung metastases from colorectal cancer. Increased (18)F-FLT uptake was related exclusively to malignant tumors. By contrast, (18)F-FDG PET was false-positive in 4 of 8 patients with benign lesions.
CONCLUSION: (18)F-FLT uptake correlates better with proliferation of lung tumors than does uptake of (18)F-FDG and might be more useful as a selective biomarker for tumor proliferation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12960187

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  110 in total

1.  The role of molecular imaging in precision radiation therapy for target definition, treatment planning optimisation and quality control.

Authors:  Giovanni Lucignani; Barbara A Jereczek-Fossa; Roberto Orecchia
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-03-30       Impact factor: 9.236

2.  Different modes of transport for 3H-thymidine, 3H-FLT, and 3H-FMAU in proliferating and nonproliferating human tumor cells.

Authors:  David A Plotnik; Lindsay E Emerick; Kenneth A Krohn; Jashvant D Unadkat; Jeffrey L Schwartz
Journal:  J Nucl Med       Date:  2010-08-18       Impact factor: 10.057

3.  PET imaging of tumor growth: not as easy as it looks.

Authors:  Anthony F Shields
Journal:  Clin Cancer Res       Date:  2012-01-24       Impact factor: 12.531

4.  From anatomical to biological target volumes: the role of PET in radiation treatment planning.

Authors:  D A X Schinagl; J H A M Kaanders; W J G Oyen
Journal:  Cancer Imaging       Date:  2006-10-31       Impact factor: 3.909

Review 5.  [18F]FLT-PET in oncology: current status and opportunities.

Authors:  Lukas B Been; Albert J H Suurmeijer; David C P Cobben; Pieter L Jager; Harald J Hoekstra; Philip H Elsinga
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-12       Impact factor: 9.236

6.  [PET/CT in radiotherapy].

Authors:  M Weckesser; S Könemann; M Brinkmann; N Willich; O Schober
Journal:  Radiologe       Date:  2004-11       Impact factor: 0.635

Review 7.  [Molecular imaging with new PET tracers].

Authors:  A J Beer; M Schwaiger
Journal:  Radiologe       Date:  2007-01       Impact factor: 0.635

8.  Is 3'-deoxy-3'-(18)F-fluorothymidine a better marker for tumour response than (18)F-fluorodeoxyglucose?

Authors:  Sven N Reske; Sandra Deisenhofer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-07       Impact factor: 9.236

9.  Monitoring tumor response with radiolabeled nucleoside analogs in a hepatoma-bearing mouse model early after doxisome(®) treatment.

Authors:  Chun-Yi Wu; Lin-Shan Chou; Pei-Chia Chan; Chung-Hsien Ho; Ming-Hsien Lin; Chih-Chieh Shen; Ren-Shyan Liu; Wuu-Jyh Lin; Hsin-Ell Wang
Journal:  Mol Imaging Biol       Date:  2013-06       Impact factor: 3.488

10.  Combined Injection of (18)F-Fluorodeoxyglucose and 3'-Deoxy-3'-[(18)F]fluorothymidine PET Achieves More Complete Identification of Viable Lung Cancer Cells in Mice and Patients than Individual Radiopharmaceutical: A Proof-of-Concept Study.

Authors:  Xiao-Feng Li; Tao Huang; Huijie Jiang; Xuemei Wang; Baozhong Shen; Xiangcheng Wang; Chin K Ng; Gregory C Postel; A Cahid Civelek
Journal:  Transl Oncol       Date:  2013-12-01       Impact factor: 4.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.